Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025

Company Overview - Evoke Pharma, Inc. is a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, particularly with its product Gimoti, a nasal spray formulation of metoclopramide [4] - Gimoti is specifically developed for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults [4] Upcoming Financial Results - The company is scheduled to release its fourth quarter and full year 2024 financial results on March 13, 2025, after market close [1] - A conference call and webcast will be held on the same day at 4:30 p.m. ET to discuss the results, with specific dial-in numbers provided for participants [2] Product Information - Diabetic gastroparesis is a gastrointestinal disorder affecting millions globally, characterized by delayed stomach emptying, which can lead to serious symptoms and complications [5] - Prior to the FDA approval of Gimoti, metoclopramide was only available in oral and injectable forms, making Gimoti the only approved drug in the U.S. for treating gastroparesis [5]